Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials.
作者信息
Zhou Jin J, Coleman Ruth, Holman Rury R, Reaven Peter
机构信息
Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA.
Carl T. Hayden Phoenix VA Health Care System (111E), Phoenix, AZ, USA.
出版信息
Diabetologia. 2020 Nov;63(11):2482-2485. doi: 10.1007/s00125-020-05273-7. Epub 2020 Sep 21.
Abstract
摘要
相似文献
1
Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials.英国前瞻性糖尿病研究（UKPDS）、控制糖尿病患者心血管风险行动（ACCORD）及糖尿病干预和并发症研究（VADT）试验中，长期血糖变异性与肾病并发症风险
Diabetologia. 2020 Nov;63(11):2482-2485. doi: 10.1007/s00125-020-05273-7. Epub 2020 Sep 21.
2
Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.2型糖尿病中的心血管疾病与强化血糖控制：推动实践走向基于证据的策略
Vasc Health Risk Manag. 2009;5:859-71. doi: 10.2147/vhrm.s4808. Epub 2009 Nov 2.
3
The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes.糖化血红蛋白（HbA1c）和餐后血糖（PPG）控制对 2 型糖尿病患者心血管结局的重要性。
Diabetes Res Clin Pract. 2010 Jul;89(1):1-9. doi: 10.1016/j.diabres.2009.12.009. Epub 2010 May 21.
4
Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT).退伍军人事务糖尿病试验（VADT）中强化血糖控制对肾脏结局的长期随访。
Diabetologia. 2018 Feb;61(2):295-299. doi: 10.1007/s00125-017-4473-2. Epub 2017 Nov 3.
5
Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.强化血糖治疗与近期数据的临床意义：血糖控制全球工作组的共识声明。
Int J Clin Pract. 2009 Oct;63(10):1421-5. doi: 10.1111/j.1742-1241.2009.02165.x.
6
Intensive glycemic control and cardiovascular disease: an update.强化血糖控制与心血管疾病：最新进展。
Nat Rev Cardiol. 2010 Jul;7(7):369-75. doi: 10.1038/nrcardio.2010.35. Epub 2010 Apr 20.
7
Intensive glucose control and cardiovascular outcomes in type 2 diabetes.强化血糖控制与 2 型糖尿病的心血管结局。
Heart Lung Circ. 2011 Oct;20(10):647-54. doi: 10.1016/j.hlc.2010.07.013. Epub 2010 Aug 31.
8
[Glycemic control and cardiovascular benefit: What do we know today?].[血糖控制与心血管获益：我们如今了解些什么？]
Dtsch Med Wochenschr. 2010 Feb;135(7):301-7. doi: 10.1055/s-0029-1244853. Epub 2010 Feb 9.
9
Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.文献中的数据表明血糖波动是一个临床问题吗？血糖波动与糖尿病血管并发症。
Diabetes Obes Metab. 2013 Sep;15 Suppl 2:3-8. doi: 10.1111/dom.12140.
10
Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes.四十年的不确定性：2型糖尿病血糖控制与心血管结局的里程碑式试验
Diab Vasc Dis Res. 2008 Sep;5(3):216-8. doi: 10.3132/dvdr.2008.036.
引用本文的文献
1
Proposed Practical Guidelines to Improve Glycaemic Management by Reducing Glycaemic Variability in People with Type 1 Diabetes Mellitus.通过降低1型糖尿病患者的血糖变异性来改善血糖管理的实用指南建议
Diabetes Ther. 2025 Apr;16(4):569-589. doi: 10.1007/s13300-025-01703-0. Epub 2025 Feb 28.
2
SPA: effectively controlling for sample relatedness in large-scale genome-wide association studies of longitudinal traits.SPA：在纵向性状的大规模全基因组关联研究中有效控制样本相关性。
Nat Commun. 2025 Feb 6;16(1):1413. doi: 10.1038/s41467-025-56669-1.
3
The Relation of Diabetes Complications to a New Interpretation of Glycaemic Variability from Continuous Glucose Monitoring in People with Type 1 Diabetes.1型糖尿病患者糖尿病并发症与连续血糖监测对血糖变异性的新解读之间的关系
Diabetes Ther. 2024 Dec;15(12):2489-2498. doi: 10.1007/s13300-024-01648-w. Epub 2024 Oct 23.
4
Prognostic value of longitudinal HbA1c variability in predicting the development of diabetic sensorimotor polyneuropathy among patients with type 2 diabetes mellitus: A prospective cohort observational study.预测 2 型糖尿病患者发生糖尿病感觉运动多发性神经病的纵向 HbA1c 变异性的预后价值：一项前瞻性队列观察研究。
J Diabetes Investig. 2024 Mar;15(3):326-335. doi: 10.1111/jdi.14131. Epub 2024 Jan 3.
5
Association of Both Short-term and Long-term Glycemic Variability With the Development of Microalbuminuria in the ACCORD Trial.ACCORD 试验中短期和长期血糖变异性与微量白蛋白尿发展的关系。
Diabetes. 2023 Dec 1;72(12):1864-1869. doi: 10.2337/db23-0374.
6
Effects of Glycemic Variability on Regulatory T Cells in Patients with Type 2 Diabetes and Kidney Disease.血糖变异性对2型糖尿病合并肾脏疾病患者调节性T细胞的影响
Diabetes Metab Syndr Obes. 2023 Aug 8;16:2365-2375. doi: 10.2147/DMSO.S413407. eCollection 2023.
7
Correlation Between Glycemic Variability and Diabetic Complications: A Narrative Review.血糖变异性与糖尿病并发症之间的相关性：一篇叙述性综述。
Int J Gen Med. 2023 Jul 21;16:3083-3094. doi: 10.2147/IJGM.S418520. eCollection 2023.
8
A platform for phenotyping disease progression and associated longitudinal risk factors in large-scale EHRs, with application to incident diabetes complications in the UK Biobank.一个用于在大规模电子健康记录中对疾病进展及相关纵向风险因素进行表型分析的平台，并应用于英国生物银行中的新发糖尿病并发症研究。
JAMIA Open. 2023 Feb 9;6(1):ooad006. doi: 10.1093/jamiaopen/ooad006. eCollection 2023 Apr.
9
Predicting diabetic nephropathy in type 2 diabetic patients using machine learning algorithms.使用机器学习算法预测2型糖尿病患者的糖尿病肾病
J Diabetes Metab Disord. 2022 Jul 26;21(2):1433-1441. doi: 10.1007/s40200-022-01076-2. eCollection 2022 Dec.
10
Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis.强化血糖控制对 ACCORD 和 VADT 试验中主要不良心血管事件的异质性治疗效果：机器学习分析。
Cardiovasc Diabetol. 2022 Apr 27;21(1):58. doi: 10.1186/s12933-022-01496-7.
本文引用的文献
1
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.强化血糖控制对 2 型糖尿病患者微血管结局的影响：来自随机对照试验的个体参与者数据的荟萃分析。
Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3. Epub 2017 Mar 30.
2
Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis.长期血糖变异性与不良结局风险：系统评价和荟萃分析。
Diabetes Care. 2015 Dec;38(12):2354-69. doi: 10.2337/dc15-1188.
3
Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis.血压变异性与心血管疾病及全因死亡率的关系：系统评价和荟萃分析。
Hypertension. 2014 Nov;64(5):965-82. doi: 10.1161/HYPERTENSIONAHA.114.03903. Epub 2014 Jul 28.
4
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.在 2 型糖尿病中，血糖变异性对大血管和微血管事件及全因死亡率的影响： ADVANCE 试验。
Diabetes Care. 2014 Aug;37(8):2359-65. doi: 10.2337/dc14-0199. Epub 2014 May 8.
5
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.强化血糖控制对 2 型糖尿病患者微血管结局的影响：ACCORD 随机试验分析。
Lancet. 2010 Aug 7;376(9739):419-30. doi: 10.1016/S0140-6736(10)60576-4. Epub 2010 Jun 30.
6
Glucose control and vascular complications in veterans with type 2 diabetes.2型糖尿病退伍军人的血糖控制与血管并发症
N Engl J Med. 2009 Jan 8;360(2):129-39. doi: 10.1056/NEJMoa0808431. Epub 2008 Dec 17.
7
Effects of intensive glucose lowering in type 2 diabetes.强化降糖对2型糖尿病的影响。
N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.
8
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.磺脲类或胰岛素强化血糖控制与传统治疗及2型糖尿病患者并发症风险的比较（英国前瞻性糖尿病研究[UKPDS 33]）。英国前瞻性糖尿病研究（UKPDS）小组
Lancet. 1998 Sep 12;352(9131):837-53.
Zotero 插件